Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by TheMadMonk on Nov 08, 2023 5:57pm

H2O on the H2S

Please, someone get a bucket of cold water and douse this red hot stock.   How is it that a few weeks ago all these complainers on various chat boards were crying that there is going to be dilution right after P2.  Now these same people are trying to bid up the price as quick and as high as possible so the we get diluted pre P2.  There are 3,118,000 warrants set to expire by the end of the year with a strike price of $1.80.  Why would anyone who truly believes this company is going to be successful with Otena, want to be diluted by nearly 6% at a measly $1.80 per share?  If management said that they were going to do a raise before the end of the year and sell more than three million shares sub two bucks, these boards would be loaded with "investors" calling for the heads of management.  Now they are all talking about "taking out the next wall" and driving the price higher.  If you truly believe in this drug/platform you would not sell before P2 or if you were a little more risk adverse you would wait until after P3.  Who cares what the price is before P2 even starts.  Hopefully the price stays below $1.80 until after the new year and we are not diluted at a lousy $100 million valuation.  Just my thoughts.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities